Recap: Recro Pharma Q3 Earnings

Shares of Recro Pharma REPH were unchanged after the company reported Q3 results.

Quarterly Results

Earnings per share increased 52.63% year over year to ($0.09), which beat the estimate of ($0.20).

Revenue of $19,287,000 declined by 23.63% from the same period last year, which beat the estimate of $16,330,000.

Guidance

Recro Pharma hasn't issued any earnings guidance for the time being.

Recro Pharma hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Nov 09, 2020

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/ej8f56o2

Recent Stock Performance

Company's 52-week high was at $19.21

Company's 52-week low was at $1.49

Price action over last quarter: down 50.00%

Company Description

Recro Pharma Inc is a contract development and manufacturing company. The company is engaged in the development, formulation, regulatory support, manufacturing, and packaging of oral solid dose drug products. Its product portfolio includes Ritalin LA; Focalin XR; Verelan PM, SR and Verapamil PM; Verapamil SR and Zohydro ER.